Ionis Pharmaceuticals Inc (IONS): who owns it and who trades it
As of Nov 16, 2026, IONS insiders reported 107 open-market sales worth $120M and 3 purchases worth $1.2M in the last 12 months, with 81% of the sale value made under pre-set 10b5-1 plans. The largest seller was Brett P Monia (CEO), with $30.3M. 7 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Ionis Pharmaceuticals
From the latest filingsOverall: about as much buying as selling. Insiders mostly sold. Famous investors mostly bought. Funds was close to even.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns IONS
510 funds and institutions reported IONS shares worth $14.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is FMR LLC (Fidelity) with 14.9%.
Funds and institutions (13F) about 100%Everyone else 0%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| FMR LLC (Fidelity) | 24.63M | 14.90% | $2B | +0% |
| Capital World Investors | 21.67M | 13.11% | $1.7B | +2% |
| BlackRock, Inc. | 10.70M | 6.48% | $849M | +3% |
| Vanguard Portfolio Management LLC | 7.86M | 4.76% | $623M | +1% |
| Wellington Management Group LLP | 7.65M | 4.63% | $607M | +20% |
| Vanguard Capital Management LLC | 7.21M | 4.36% | $572M | +1% |
| Two Sigma Investments, LP | 6.25M | 3.78% | $496M | +7% |
| Royal Bank of Canada | 6.18M | 3.74% | $490M | +63% |
| State Street Corp | 4.33M | 2.62% | $344M | +8% |
| T. Rowe Price Investment Management, Inc. | 3.96M | 2.40% | $314M | -36% |
| Geode Capital Management, LLC | 3.58M | 2.17% | $295M | -10% |
| T. Rowe Price Associates | 3.18M | 1.93% | $252M | +5% |
| JPMorgan Chase & Co | 2.67M | 1.62% | $216M | – |
| Artisan Partners Limited Partnership | 2.64M | 1.60% | $209M | +28% |
| Tweedy, Browne Co LLC | 2.28M | 1.38% | $181M | +0% |
| Deep Track Capital, LP | 2.20M | 1.33% | $174M | +13% |
| Goldman Sachs Group Inc | 2.11M | 1.28% | $167M | +24% |
| Baker Bros. Advisors LP | 2.05M | 1.24% | $162M | No change |
| Deerfield Management Company, L.P. | 1.98M | 1.20% | $157M | No change |
| American Century Companies Inc | 1.95M | 1.18% | $154M | +17% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, IONS insiders reported $1.2M of open-market purchases and $120M of sales. 81% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Michael R Hayden | Director | Purchase | 5,000 | $29.64 | $148K | Form 4 |
| Oct 16, 2026 | Shannon L. Devers | Vice president | Sale | 1,357 | $43.54 | $59.1K | Form 4 |
| Oct 16, 2026 | Eric Swayze | Vice president | Sale | 53 | $43.54 | $2.3K | Form 4 |
| Jul 31, 2026 | Michael R Hayden | Director | Purchase | 5,000 | $51.60 | $258K | Form 4 |
| Jul 30, 2026 | Michael R Hayden | Director | Purchase | 15,000 | $53.38 | $801K | Form 4 |
| Jul 7, 2026 | C Frank Bennett | Vice president | Sale plan | 15,000 | $85.46 | $1.3M | Form 4 |
| Jul 7, 2026 | C Frank Bennett | Vice president | Sale plan | 5,536 | $83.58 | $463K | Form 4 |
| Jul 7, 2026 | Allene M. Diaz | Director | Sale plan | 10,111 | $85.42 | $864K | Form 4 |
| Jul 7, 2026 | Holly B. Kordasiewicz | Vice president | Sale plan | 362 | $84.30 | $30.5K | Form 4 |
| Jul 1, 2026 | Joseph Klein III | Director | Sale plan | 99 | $79.45 | $7.9K | Form 4 |
| Jul 1, 2026 | Joseph Klein III | Director | Sale plan | 11,419 | $79.04 | $903K | Form 4 |
| Jun 26, 2026 | Joseph Baroldi | Vice president | Sale plan | 5,635 | $80.16 | $452K | Form 4 |
| Jun 26, 2026 | Patrick R. O'Neil | Vice president | Sale plan | 3,069 | $80.00 | $246K | Form 4 |
| Jun 26, 2026 | Eugene Schneider | Vice president | Sale plan | 26,000 | $81.05 | $2.1M | Form 4 |
| Jun 26, 2026 | Brett P Monia | CEO | Sale plan | 50,000 | $80.59 | $4M | Form 4 |
| Jun 25, 2026 | Brett P Monia | CEO | Sale plan | 21,072 | $78.49 | $1.7M | Form 4 |
| Jun 25, 2026 | Eric Swayze | Vice president | Sale plan | 10,602 | $79.18 | $839K | Form 4 |
| Jun 24, 2026 | Brett P Monia | CEO | Sale plan | 14,565 | $78.41 | $1.1M | Form 4 |
| Jun 15, 2026 | Spencer R Berthelsen | Director | Sale plan | 8,000 | $73.49 | $588K | Form 4 |
| Jun 12, 2026 | Holly B. Kordasiewicz | Vice president | Sale plan | 19,842 | $74.05 | $1.5M | Form 4 |
| Jun 12, 2026 | Holly B. Kordasiewicz | Vice president | Sale plan | 41,004 | $73.09 | $3M | Form 4 |
| Jun 1, 2026 | Spencer R Berthelsen | Director | Sale plan | 8,000 | $75.67 | $605K | Form 4 |
| May 14, 2026 | Brett P Monia | CEO | Sale plan | 3,220 | $78.68 | $253K | Form 4 |
| May 13, 2026 | Brett P Monia | CEO | Sale plan | 1,316 | $78.01 | $103K | Form 4 |
| May 4, 2026 | Joseph Loscalzo | Director | Sale plan | 17,781 | $75.58 | $1.3M | Form 4 |
| May 4, 2026 | Joseph Loscalzo | Director | Sale plan | 59,508 | $74.90 | $4.5M | Form 4 |
| May 1, 2026 | Joseph Klein III | Director | Sale plan | 8,680 | $73.35 | $637K | Form 4 |
| May 1, 2026 | Joseph Klein III | Director | Sale plan | 1,431 | $74.45 | $107K | Form 4 |
| Apr 28, 2026 | Joseph Baroldi | Vice president | Sale plan | 1,626 | $71.79 | $117K | Form 4 |
| Apr 16, 2026 | Kyle Jenne | Vice president | Sale | 4,902 | $75.17 | $368K | Form 4 |
| Apr 16, 2026 | Brian Birchler | Vice president | Sale | 973 | $75.04 | $73K | Form 4 |
| Apr 16, 2026 | Joseph Baroldi | Vice president | Sale | 5,619 | $74.56 | $419K | Form 4 |
| Apr 15, 2026 | B Lynne Parshall | Director | Sale plan | 534 | $76.97 | $41.1K | Form 4 |
| Apr 15, 2026 | B Lynne Parshall | Director | Sale plan | 4,466 | $76.19 | $340K | Form 4 |
| Apr 2, 2026 | Shannon L. Devers | Vice president | Sale plan | 6,193 | $74.05 | $459K | Form 4 |
| Apr 1, 2026 | Joseph Klein III | Director | Sale plan | 2,216 | $75.95 | $168K | Form 4 |
| Apr 1, 2026 | Joseph Klein III | Director | Sale plan | 20,105 | $75.50 | $1.5M | Form 4 |
| Mar 19, 2026 | Eugene Schneider | Vice president | Sale plan | 5,812 | $70.97 | $412K | Form 4 |
| Mar 17, 2026 | Elizabeth L Hougen | CFO | Sale plan | 10,172 | $73.21 | $745K | Form 4 |
| Mar 16, 2026 | Elizabeth L Hougen | CFO | Sale plan | 205,608 | $72.38 | $14.9M | Form 4 |
| Mar 16, 2026 | Elizabeth L Hougen | CFO | Sale plan | 9,440 | $72.77 | $687K | Form 4 |
| Mar 10, 2026 | Brett P Monia | CEO | Sale plan | 16,512 | $75.47 | $1.2M | Form 4 |
| Mar 10, 2026 | Brett P Monia | CEO | Sale plan | 17,591 | $76.34 | $1.3M | Form 4 |
| Mar 10, 2026 | Kyle Jenne | Vice president | Sale plan | 16,086 | $76.30 | $1.2M | Form 4 |
| Mar 10, 2026 | Kyle Jenne | Vice president | Sale plan | 21,191 | $75.50 | $1.6M | Form 4 |
| Mar 9, 2026 | Patrick R. O'Neil | Vice president | Sale plan | 10,148 | $75.25 | $764K | Form 4 |
| Mar 9, 2026 | Brett P Monia | CEO | Sale plan | 1,684 | $75.58 | $127K | Form 4 |
| Mar 9, 2026 | Brett P Monia | CEO | Sale plan | 117,604 | $75.26 | $8.9M | Form 4 |
| Mar 9, 2026 | Brett P Monia | CEO | Sale plan | 7,382 | $74.11 | $547K | Form 4 |
| Mar 4, 2026 | Joseph Loscalzo | Director | Sale plan | 200 | $80.00 | $16K | Form 4 |
| Mar 4, 2026 | Joseph Baroldi | Vice president | Sale plan | 238 | $80.00 | $19K | Form 4 |
| Mar 4, 2026 | Joseph Baroldi | Vice president | Sale plan | 201 | $80.00 | $16.1K | Form 4 |
| Mar 3, 2026 | Joseph Loscalzo | Director | Sale plan | 832 | $80.33 | $66.8K | Form 4 |
| Mar 3, 2026 | Joseph Klein III | Director | Sale plan | 13,526 | $79.17 | $1.1M | Form 4 |
| Mar 3, 2026 | Joseph Klein III | Director | Sale plan | 6,794 | $80.00 | $544K | Form 4 |
| Mar 3, 2026 | Joseph Klein III | Director | Sale plan | 1,012 | $80.82 | $81.8K | Form 4 |
| Mar 3, 2026 | Allene M. Diaz | Director | Sale plan | 14,608 | $79.88 | $1.2M | Form 4 |
| Mar 3, 2026 | Allene M. Diaz | Director | Sale plan | 1,005 | $80.80 | $81.2K | Form 4 |
| Mar 3, 2026 | Allene M. Diaz | Director | Sale plan | 39,265 | $79.11 | $3.1M | Form 4 |
| Mar 3, 2026 | Shannon L. Devers | Vice president | Sale plan | 14,321 | $79.12 | $1.1M | Form 4 |
| Mar 3, 2026 | Shannon L. Devers | Vice president | Sale plan | 5,030 | $80.00 | $402K | Form 4 |
| Mar 3, 2026 | Shannon L. Devers | Vice president | Sale plan | 755 | $80.84 | $61K | Form 4 |
| Mar 3, 2026 | C Frank Bennett | Vice president | Sale plan | 71,600 | $79.10 | $5.7M | Form 4 |
| Mar 3, 2026 | C Frank Bennett | Vice president | Sale plan | 12,687 | $79.88 | $1M | Form 4 |
| Mar 3, 2026 | C Frank Bennett | Vice president | Sale plan | 802 | $80.76 | $64.8K | Form 4 |
| Mar 3, 2026 | Joseph Baroldi | Vice president | Sale plan | 2,088 | $80.41 | $168K | Form 4 |
| Mar 3, 2026 | Joseph Baroldi | Vice president | Sale plan | 36 | $81.01 | $2.9K | Form 4 |
| Mar 3, 2026 | Joseph Baroldi | Vice president | Sale plan | 4,096 | $79.36 | $325K | Form 4 |
| Feb 13, 2026 | Eric Swayze | Vice president | Sale plan | 6,207 | $82.07 | $509K | Form 4 |
| Feb 13, 2026 | Eric Swayze | Vice president | Sale plan | 9,435 | $81.56 | $770K | Form 4 |
| Feb 11, 2026 | B Lynne Parshall | Director | Sale plan | 5,000 | $82.72 | $414K | Form 4 |
| Feb 6, 2026 | Brett P Monia | CEO | Sale plan | 29,430 | $85.79 | $2.5M | Form 4 |
| Feb 2, 2026 | C Frank Bennett | Vice president | Sale plan | 16,463 | $83.03 | $1.4M | Form 4 |
| Feb 2, 2026 | C Frank Bennett | Vice president | Sale plan | 48,626 | $83.03 | $4M | Form 4 |
| Feb 2, 2026 | C Frank Bennett | Vice president | Sale plan | 20,000 | $82.60 | $1.7M | Form 4 |
| Jan 30, 2026 | Eric Swayze | Vice president | Sale | 6,179 | $82.93 | $512K | Form 4 |
| Jan 30, 2026 | Eugene Schneider | Vice president | Sale | 6,179 | $83.45 | $516K | Form 4 |
| Jan 30, 2026 | Patrick R. O'Neil | Vice president | Sale | 6,179 | $83.53 | $516K | Form 4 |
| Jan 30, 2026 | Brett P Monia | CEO | Sale | 62,970 | $82.72 | $5.2M | Form 4 |
| Jan 30, 2026 | Elizabeth L Hougen | CFO | Sale | 6,988 | $83.24 | $582K | Form 4 |
| Jan 30, 2026 | Brian Birchler | Vice president | Sale | 6,179 | $83.03 | $513K | Form 4 |
| Jan 30, 2026 | C Frank Bennett | Vice president | Sale | 5,885 | $82.95 | $488K | Form 4 |
| Jan 30, 2026 | Joseph Baroldi | Vice president | Sale | 5,296 | $82.96 | $439K | Form 4 |
| Jan 22, 2026 | Shannon L. Devers | Vice president | Sale plan | 3,977 | $81.34 | $323K | Form 4 |
| Jan 16, 2026 | Eric Swayze | Vice president | Sale | 9,884 | $75.34 | $745K | Form 4 |
| Jan 16, 2026 | Eric Swayze | Vice president | Sale | 49 | $75.97 | $3.7K | Form 4 |
| Jan 16, 2026 | Eugene Schneider | Vice president | Sale | 9,302 | $75.59 | $703K | Form 4 |
| Jan 16, 2026 | Patrick R. O'Neil | Vice president | Sale | 9,191 | $75.84 | $697K | Form 4 |
| Jan 16, 2026 | Brett P Monia | CEO | Sale | 44,034 | $74.82 | $3.3M | Form 4 |
| Jan 16, 2026 | Holly B. Kordasiewicz | Vice president | Sale | 4,141 | $75.66 | $313K | Form 4 |
| Jan 16, 2026 | Kyle Jenne | Vice president | Sale | 1,823 | $75.96 | $138K | Form 4 |
| Jan 16, 2026 | Elizabeth L Hougen | CFO | Sale | 12,922 | $75.22 | $972K | Form 4 |
| Jan 16, 2026 | Shannon L. Devers | Vice president | Sale | 8,353 | $75.95 | $634K | Form 4 |
| Jan 16, 2026 | Brian Birchler | Vice president | Sale | 8,480 | $75.11 | $637K | Form 4 |
| Jan 16, 2026 | C Frank Bennett | Vice president | Sale | 8,977 | $75.15 | $675K | Form 4 |
| Jan 16, 2026 | Joseph Baroldi | Vice president | Sale | 6,907 | $75.75 | $523K | Form 4 |
| Jan 16, 2026 | Joseph Baroldi | Vice president | Sale | 1,149 | $75.78 | $87.1K | Form 4 |
| Jan 7, 2026 | Shannon L. Devers | Vice president | Sale plan | 25,545 | $85.36 | $2.2M | Form 4 |
| Jan 7, 2026 | Shannon L. Devers | Vice president | Sale plan | 2,101 | $85.36 | $179K | Form 4 |
| Jan 7, 2026 | Shannon L. Devers | Vice president | Sale plan | 9,264 | $84.62 | $784K | Form 4 |
Latest 100 of 110 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Brett P Monia | Chief Executive Officer, Director | – | $30.3M | Jun 26, 2026 |
| Elizabeth L Hougen | EVP, Finance & CFO | – | $17.9M | Mar 17, 2026 |
| C Frank Bennett | EVP, Chief Scientific Officer | – | $16.7M | Jul 7, 2026 |
| Shannon L. Devers | EVP, Chief Human Resources Ofc | – | $8.2M | Oct 16, 2026 |
| Joseph Loscalzo | Director | – | $5.9M | May 4, 2026 |
| Joseph Klein III | Director | – | $5.4M | Jul 1, 2026 |
| Eric Swayze | EVP Research | – | $5.2M | Oct 16, 2026 |
| Allene M. Diaz | Director | – | $5.2M | Jul 7, 2026 |
| Holly B. Kordasiewicz | EVP, Chief Development Officer | – | $4.8M | Jul 7, 2026 |
| Eugene Schneider | EVP, Chf Clinical Develop Ofcr | – | $3.7M | Jun 26, 2026 |
| Kyle Jenne | EVP, Chf GL Pdt Str Ofcr | – | $3.3M | Apr 16, 2026 |
| Joan E Herman | Director | – | $3.2M | Nov 19, 2025 |
| Joseph Baroldi | EVP, Chief Business Officer | – | $2.6M | Jun 26, 2026 |
| Joseph H Wender | Director | – | $2.3M | Dec 1, 2025 |
| Patrick R. O'Neil | EVP CLO & General Counsel | – | $2.2M | Jun 26, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
IONS short interest
High short interest. 12.7% of IONS shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 32%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 21.17M IONS shares were sold short, 12.7% of the shares outstanding, up 2.5% from the report before. At the average daily volume of 2.52M shares, buying them all back would take about 8.4 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 21.17M | 12.74% | +2% | 2.52M | 8.4 |
| Oct 15, 2026 | 20.65M | 12.43% | -8% | 2.70M | 7.7 |
| Sep 30, 2026 | 22.51M | 13.54% | +8% | 4.88M | 4.6 |
| Sep 15, 2026 | 20.89M | 12.57% | -0% | 4.02M | 5.2 |
| Aug 31, 2026 | 20.92M | 12.59% | +0% | 2.28M | 9.2 |
| Aug 14, 2026 | 20.91M | 12.58% | -3% | 2.17M | 9.6 |
| Jul 31, 2026 | 21.47M | 12.92% | +7% | 3.38M | 6.3 |
| Jul 15, 2026 | 20.04M | 12.13% | +15% | 5.45M | 3.7 |
| Jun 30, 2026 | 17.43M | 10.54% | -2% | 2.38M | 7.3 |
| Jun 15, 2026 | 17.76M | 10.74% | +5% | 1.67M | 10.6 |
| May 29, 2026 | 16.99M | 10.28% | +6% | 1.70M | 10.0 |
| May 15, 2026 | 16.09M | 9.73% | -1% | 1.61M | 10.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Ionis Pharmaceuticals company events
Ionis Pharmaceuticals filed 20 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026ResultsReleased financial results. Filing
- Oct 23, 2026AnnouncementIonis’ partner, Roche, announced late-breaking oral presentation data from the ongoing Phase 3 IMAgINATION study in adults with primary IgAN receiving optimized standard of care, demonstrating that investigational sefaxersen achieved a statistically significant and clinically meaningful 43.1%… Filing
- Oct 21, 2026AnnouncementIonis reported that its partner, GSK, announced that the FDA has approved HIBSAGO™ (bepirovirsen) for the treatment of CHB virus infection in combination with NrtI therapy in adult patients without cirrhosis, receiving Nrtl therapy for at least 6 months, who have suppressed HBV DNA, and with HBsAg… Filing
- Sep 23, 2026AnnouncementIonis and its partner, Roche, announced positive prespecified interim results from the ongoing Phase 3 IMAgINATION study evaluating investigational sefaxersen in adults with IgAN. The study met its primary endpoint with sefaxersen achieving statistically significant and clinically meaningful… Filing
- Sep 4, 2026AnnouncementIonis announced that its partner, Novartis, reported that the pelacarsen Phase 3 Lp(a)HORIZON study, a pioneering cardiovascular outcomes trial, did not meet its primary endpoint of reducing the risk of cardiovascular events, a composite of cardiovascular death, non-fatal myocardial infarction… Filing
- Sep 4, 2026AnnouncementIonis announced that the U.S. FDA has approved ZANVASTRO™ (zilganersen) for the treatment of AxD in pediatric and adult patients. Filing
- Jul 29, 2026ResultsReleased financial results. Filing
- Jul 10, 2026AnnouncementShared information with investors. Filing
- Jul 9, 2026AnnouncementIonis announced that the CARDIO-TTRansform Phase 3 trial for eplontersen in patients with ATTR-CM did not meet the primary efficacy endpoint of the composite outcome of CV mortality and recurrent CV clinical events up to Week 140 compared with placebo. Filing
- Jun 24, 2026AnnouncementIonis announced that the U.S. FDA has approved TRYNGOLZA® (olezarsen) as an adjunct to diet to reduce triglycerides and the risk of acute pancreatitis in adults with sHTG. TRYNGOLZA is available in a 50 mg or 80 mg dose and is self-administered once monthly via an autoinjector. sHTG is… Filing
- Jun 12, 2026AnnouncementIonis Pharmaceuticals, Inc. shared positive new data from the open-label extension study of CORE and CORE2 evaluating olezarsen in people with severe hypertriglyceridemia during an oral presentation at the National Lipid Association Scientific Sessions in Chicago. Filing
- Jun 8, 2026LeadershipThe Board of Directors of Ionis Pharmaceuticals, Inc. appointed Ludwig N. Hantson as a member of the Company’s Board effective June 4, 2026, immediately following the Company’s 2026 Annual Meeting of Stockholders. Filing
- May 28, 2026AnnouncementIonis announced that its partner, GSK, reported positive pivotal data for bepirovirsen, an investigational ASO for the treatment of CHB. Results from the two Phase 3 trials, B-Well 1 and B-Well 2, were simultaneously published in the New England Journal of Medicine and presented at the European… Filing
- Apr 29, 2026ResultsReleased financial results. Filing
- Apr 21, 2026AnnouncementWe announced additional positive results from the pivotal study of zilganersen in children and adults living with AxD, a rare, progressive and often fatal neurological condition with no approved disease-modifying treatments. Filing
- Mar 9, 2026LeadershipB. Lynne Parshall, a member of the Board of Directors of Ionis Pharmaceuticals, Inc., and member of the Compliance Committee and Finance Committee of the Board, notified the Company that she will be retiring from the Board at the end of her current term and not seeking re-election at the Company’s… Filing
- Feb 25, 2026ResultsReleased financial results. Filing
- Jan 12, 2026ResultsReleased financial results. Filing
- Jan 7, 2026AnnouncementWe announced that our partner, GSK, reported positive results from two pivotal Phase 3 studies, B-Well 1 and B-Well 2, evaluating the safety and efficacy of bepirovirsen, an investigational ASO for the treatment of CHB. The studies included over 1,800 patients from 29 countries. Filing
- Nov 17, 2025AgreementIonis Pharmaceuticals, Inc. completed its previously announced private offering of $770.0 million of 0.00% Convertible Senior Notes due 2030, including the exercise in full of the initial purchasers’ option to purchase up to an additional $70.0 million principal amount of Notes. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Ionis Pharmaceuticals financials
Famous investors that hold IONS
7 of the 50 well-known investors we track reported holding IONS in their latest 13F filing. The largest position is Ken Griffin's, worth $180M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Ken Griffin · Citadel Advisors | Q3 2026 | 4.03M | $180M | 0.1% | +1604% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.23M | $54.8M | 0.1% | New |
| Cathie Wood · ARK Investment Management | Q3 2026 | 923,162 | $41.2M | 0.2% | +207% |
| Israel Englander · Millennium Management | Q3 2026 | 750,785 | $33.5M | 0.0% | +160% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 354,214 | $15.8M | 0.0% | -37% |
| Ken Fisher · Fisher Asset Management | Q3 2026 | 182,997 | $8.2M | 0.0% | +33% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 23,882 | $1.1M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
Questions about Ionis Pharmaceuticals Inc (IONS) stock
Who owns the most IONS stock?
The largest reported owner of Ionis Pharmaceuticals Inc (IONS) is FMR LLC (Fidelity), with 14.9% of the company. In total, 510 funds and institutions reported holding IONS at the end of Q2 2026, together about 100% of the shares. See the largest owners.
Are IONS insiders buying or selling?
In the last 12 months, IONS insiders reported 3 open-market purchases worth $1.2M and 107 sales worth $120M. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in IONS?
As of Oct 30, 2026, 21.17M IONS shares were sold short, 12.7% of the shares outstanding, up 2.5% from the report before. At the average daily volume of 2.52M shares, buying them all back would take about 8.4 trading days (days to cover). See the history.
Which famous investors hold IONS?
7 of the 50 well-known investors we track reported IONS in their latest 13F filing, including Ken Griffin, Steve Cohen, Cathie Wood. The largest position is worth $180M. See all holders.
Executive pay
Ionis Pharmaceuticals's chief executive was paid a total of $13.4M for the year ended Dec 31, 2025, down 13% from $15.4M the year before. In the last 12 months, Ionis Pharmaceuticals's executives and directors bought $1.2M of stock on the open market and sold $120M.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.